Incidence of Positive Human Papillomavirus High Risk in Negative Cytology Result: Insidensi Kejadian Human Papillomavirus RisikoTinggi Positif pada Hasil Sitologi Negatif by Indarti, Junita et al.
Incidence of Positive Human Papillomavirus  High Risk 
in Negative Cytology Result
Insidensi Kejadian Human Papillomavirus RisikoTinggi Positif 
pada Hasil Sitologi Negatif
Junita Indarti, Darrell Fernando, Finish Fernando, Ribkhi A. Putri
Anggara Mahardika, Muhammad Ikhsan
Department Obstetrics and Gynecology
Faculty of Medicine Universitas Indonesia
Dr. Cipto Mangunkusumo General Hospital
Jakarta
Correspondence author: Junita Indarti; muh.ikhsan.md@gmail.com
Research Article
Vol 7, No 4 
October 2019 Incidence of Positive Human 244
Abstract
Objective : To report the incidence of positive HPV high risk 
in negative cytology result.
Methods : We collected 83 women underwent liquid-based 
cytology (LBC) and HPV DNA examination at the same time. 
We were using Diag Cor GenoFlow Human Papillomavirus 
Array Test (GenoFlow), a novel HPV test based on PCR 
and "Flow-through" hybridization that can identify 33 HPV 
subtypes: 18 types of High risk HPV such as 16, 18, 31, 33, 
35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 81 and 82.
Results : We grouped the subjects based on age below or 
equal to 30 years old (n=6) and above 30 years old (n=77). 
We found a signifi cant difference in HPV DNA result within 
this group (P = 0.034), with 19.3% had HPV DNA type 16 and 
18 in a group of age above 30 years old. Our study showed 
that 27 women (32.5%) underwent screening for cervical 
cancer having negative LBC result but showed positive HPV 
DNA positive.
Conclusions : We found a signifi cant difference in HPV DNA 
test result among women above 30 years old. Co-testing of 
Pap and HPV DNA is needed, especially if HPV DNA type 16 
and 18 were found among negative Pap results.
Keywords : Cervical cancer, HPV DNA, incidence, LBC, 
screening. 
Abstrak
Tujuan : Melaporkan insidensi dari HPV risiko tinggi yang 
positif pada hasil sitologi negatif.
Metode : Kami mengumpulkan 83 perempuan yang 
menjalani liquid based cytology (LBV) dan pemeriksaan HPV 
DNA pada waktu yang bersamaan. Dengan menggunakan 
DiagCor GenoFlow Human Papilloma Virus Array Test 
(GenoFlow), yaitu sebuah uji HPV terbaru yang berbasis PCR 
dan “Flow-throug” hybridization dapat mengidentifi kasi 33 
subtipe HPV: 18 tipe HPV risiko tinggi seperti 16, 18, 31, 33, 
35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 81 dan 82.
Hasil : Kami mengelompokkan subjek berdasarkan usia di 
bawah atau setara 30 tahun dan di atas 30 tahun (n=77). 
Kami menemukan perbedaan signifi kan dari hasil HPV DNA 
dalam kelompok ini (P=0,034), dengan 19.3% memiliki 
HPV DNA tipe 16 dan 18 dalam kelompok usia diatas 30 
tahun. Penelitian ini menunjukkan 27 perempuan (32,5%) 
menjalani skrining kanker serviks memiliki hasil LBC yang 
negatif namun menunjukkan HPV DNA positif.
Kesimpulan : Terdapat perbedaan signifi kan dari uji 
HPV DNA pada wanita usia diatas 30 tahun. Pemeriksaan 
bersamaan antara Pap dan HPV DNA dibutuhkan terutama 
ketika HPV DNA tipe 16 dan 18 ditemukan pada hasil Pap 
negatif.
Kata kunci : HPV DNA, insidensi, kanker serviks, LBC, 
skrining. 
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INTRODUCTION
Indonesian population is estimated at around 
93.15 million, where the majority of women with 
age above 15 years old, has an increased risk 
of cervical cancer. Cervical cancer is the second 
most affecting cancer in women in Indonesia, 
with the incidence of 20,928 per year since 2012. 
Based on the age category in Indonesia, cervical 
cancer also the second most frequent female 
cancer in women at the age of 14-55 years old. 
Approximately 4% of female in Indonesia is 
infected with Human Papilloma Virus (HPV) type 
16/18 which cause 87%  of cervical cancer.1
In the last 40 years in the United States, 
yearly screening with Pap smear will dramatically 
decrease the morbidity and mortality related 
to cervical cancer.2 In Indonesia, the diagnostic 
methods such as Pap smear, Visual Inspection of 
acetic acid3, and also HPV Deoxyribonucleic Acid 
(DNA) were also used with the screening number 
24.4% until 2017, with the most common in the 
age 30 to 50 years old and fi ve years screening 
period.1 Worldwide, two type of HPV (16 and 18) 
cause more than 70% of cervical cancer, 41-67% 
High-Grade Cervical Lesions (HSIL) and 16-32% 
Low-Grade Cervical Lesion (LSIL).
DiagCor GenoFlow Human Papillomavirus 
Array Test (Geno Flow) is a novel HPV test based 
on PCR and “Flow-through” hybridization that 
can identify 33 HPV subtypes4, 18 types of High 
risk HPV such as16, 18, 31, 33, 35, 39, 45, 51, 52, 
53, 56, 58,59, 66,68, 73, 81 and 82 that count as 
the cause of the other 20% of cervical cancer5,6 
and the low risk HPV 15 type such as 6, 11, 26, 40, 
42, 43, 44. 54, 55, 57, 61, 70, 71, 72, and 84.6
The newest guideline based on American 
Society for Colposcopy and Cervical Pathology 
ASCCP and American College of Obstetricians 
and Gynecologists ACOG recommended the 
DNA-HPV High-Risk examination as an additional 
routine examination in pap smear screening in 
women with the age of 30 or more. 2,7 NA-HPV has 
a potential role in the three main areas such as as 
the case triage inpatients with abnormal cytology 
LSIL or ASCUS, as monitoring for the post-
therapy in patients with Cervical Intraepithelial 
Neoplasia8, and the last one as primary screening 
for the alternative or additional Pap smear.7
Food Drug Administration (FDA) in the United 
States agree in combination examination of  DNA-
HPV and cytology inpatients with the age of 30 or 
above. The age 30 or above was the critical ages 
for screening as the 30 years and below had the 
lower risk for invasive cervical cancer although 
has the high possibility to get the HPV infection 
temporarily.
Furthermore, the prevalence of HPV infection 
in women at the of 30 or above is lower than 
women with the younger age that causes 
increasing number in specifi city in DNA-HPV 
examinaion.9
Although there is already an agreement in the 
screening age of 30, there is still an unclear issue 
whether there is still the same pattern in the age 
above 30 as long the women is still in screening 
methods. This is due to the score of pre-neoplastic 
incidence in this age group was low.2 Based on 
the newest study, with Athena calculation that 
contributed as much as 35.000 women age 
30 years and above, reported the decreasing 
number of high-risk DNA-HPV detection related 
with increasing age in all category with all degree 
of CIN that proves with pathological that shows 
the decreasing number dramatically in the HPV 
type 16 detection. The cohort study with high-
risk DNA-HPV detection and cervical problem in 
perimenopause women (35 to 60 years old) shows 
the same results with decreasing correlation with 
the increasing age.2
The purpose of this paper is to assess the 
relationship between high-risk DNA HPV 
detection and normal cytology based on age 
category.
METHODS
Every woman who came to Colposcopy clinic in 
the department of Obstetrics and Gynecology 
clinic in January to December 2016 to participate 
in the cohort prospective study to study the 
natural history of HPV infection along with the 
transition age in perimenopause women. Inclusion 
criteria in this study are female age 35 to 60 
years, no cervical cancer, got information about 
the study and willing to participate in the study. 
The exclusion criteria of the study were pregnant 
women, intending to get pregnant, history of 
organ transplantation, and HIV positive.
After the subject sign the informed consent, 
the subject will complete the basic data and 
gynaecology examination the ethical committee 
of Faculty of Medicine Universitas Indonesia. 
The history of sociodemographic characteristic, 
reproduction history and menstruation, sexual 
history and the latest sexual activity, cigarette 
history were compiled in the anamnesis. The 
cervical screening and medical therapy history 
that include the result of HPV and Pap smear 
before, colposcopy, and therapy-related with 
the condition was also collected. All of the 
examinations were performed by the gynaecology 
consultant. The examination protocol of DNA 
HPV was done by speculum and cervical brush 
examination. With transport by the standard 
medium transport (clinical pathology), and got 
approval from the research ethics committee. 
We were using GenoFlow Human Papillomavirus 
Array Test for identifying HPV DNA subtype. 
The lowest detection limits of the GF assay 
for HPV16 and HPV18 were 25 copies and 20 
copies, respectively, with a sensitivity of 80% and 
specifi city of 23%.10
Cervical Abnormality Detection 
and HPV Infection
The Pap smear classifi cation was arranged to the 
severe level such as negative, ASCUS, LSIL, ASC-H, 
HSIL or cancer. At the cytology, classifi cation is 
based on ASCUS or above ASCUS. 
The extraction of the DNA-HPV detection and 
genotyping from the cervical specimen was by 
using GenoFlow Human Papillomavirus Array 
Test. For this analysis, HPV type 16, 18, 31, 33, 35, 
39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 81 and 
82 are classifi ed as high risk HPV. The other HPV 
besides that type was classifi ed as negative even 
the result is positive.
Statistical Analysis
Analysis of statistic using SPSS version 22 for 
analyzing the relationship between the variables. 
We analyze the relationship between LBC result 
and HPV DNA test, and as well as LBC result and 
HPV DNA type.
RESULTS
We recruited 83 women who underwent LBC and 
HPV DNA examination. Our study showed that 
women having positive HPV DNA test were around 
40 to 45 years of age, with the age of fi rst sexual 
intercourse around 20 years old. Most of our HPV 
DNA positive population (56.5%) is having a one-
time marriage, and work as housewives (28.9%) 
(Table 1).
Table 1. Demographic Data
HPV DNA Positive
%
Age (years)
Parity
Abortus
Living Child
Sexual Partner(s)
Single
Multiple
Duration of Mariage (years)
Age of First Sexual Contact
Cigarette Smoking
yes
no
Occupation
Housewife
Private Sector
Governmental Sector
Contraception
None
Sterilization
IUD
DMPA
Condom
OCP
Implant
43 (95CI 40.38 – 45.62)
2 (95CI 1.67 – 2.49)
0 (95CI .13 – .43)
2 (95CI 1.58 – 2.30)
46 (55.4)
4 (4.8)
20 (95CI 17.55 – 23.97)
20.5 (95CI 20.43 – 22.85)
11 (13.3)
39 (46.9)
24 (28.9)
21 (25.3)
5 (10.0)
24 (28.9)
2 (2.4)
13 (15.7)
6 (7.2)
0 (0)
4 (4.8)
1 (1.2)
45 (95CI 41.16 – 48.84)
2 (95CI 1.73 – 2.64)
0 (95CI .07 – .66)
2 (95CI 1.56 – 2.31)
31 (37.3)
2 (2.4)
24 (95CI 18.01 – 25.87)
20 (95CI 19.89 – 23.5)
2 (2.4)
31 (37.4)
18 (21.7)
9 (10.8)
6 (18.2)
14 (16.9)
1 (1.2)
12 (14.5)
4 (4.8)
1 (1.2)
1 (1.2)
0 (0)
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
HPV DNA Negative
%
P- value
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From our data, the eldest subject was 68 years 
old, and the youngest was 20 years old. We 
grouped the subjects by age below or equal to 
30 years old (n=6) and above 30 years old (n=77). 
We found signifi cant difference HPV DNA result 
within this grouping (P = 0.034), with 19.3% had 
HPV DNA type 16 and 18 in the group of age 
above 30 years old (Table 2).
Our study showed that 27 women (32.5%) 
underwent screening for cervical cancer having 
negative LBC result but showed positive HPV 
DNA positive. Only seven women (8.4%) that 
HPV DNA type that recorded positive in our study 
population mostly is HPV type 59 found in  19 
women (22.8%), and yet 12 (14.5%) out of them 
showed negative LBC result. Only three women 
(3.6%) with HPV DNA of type 16 showed LBC 
result of HSIL (Table 4). 
showed HSIL from LBC result, having HPV DNA 
test positive. There is no signifi cant relation 
(p<0.05) between LBC result and HPV DNA result 
(Table 3).
Table 2. Relationship between Age below or Above 30 Years Old and HPV DNA Test
Table 3. Relationship between LBC Result and HPV DNA Test
Table 4. Relationship between HPV DNA Type and LBC Result
*Chi-square test, relations between Age below or above 30 years old and HPV DNA result
Agey o HPV DNA High Risk
HPV DNA Result
HPV 
DNA 
Type
LBC Result
HSIL LSIL ASCH ASCUS Negative Total P-value
3 (3.6)
1 (1.2)
2 (2.4)
1 (1.2)
1 (1.2)
0 (0)
0 (0)
0 (0)
1 (1.2)
1 (1.2)
0 (0)
0 (0)
0 (0)
1 (1.2)
1 (1.2)
16
18
58
59
52
35
56
66
68
51
45
81
53
33
39
1 (1.2)
0 (0)
0 (0)
0 (0)
1 (1.2)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
1 (1.2)
1 (1.2)
0 (0)
3 (3.6)
3 (3.6)
0 (0)
3 (3.6)
4 (4.8)
4 (4.8)
1 (1.2)
2 (2.4)
0 (0)
0 (0)
1 (1.2)
0 (0)
1 (1.2)
0 (0)
1 (1.2)
3 (3.6)
2 (2.4)
0 (0)
1 (1.2)
2 (2.4)
2 (2.4)
0 (0)
0 (0)
1 (1.2)
0 (0)
0 (0)
0 (0)
8 (9.6)
3 (3.6)
0 (0)
12 (14.5)
11 (13.3)
1 (1.2)
3 (3.6)
10 (12.0)
9 (10.8)
2 (2.4)
2 (2.4)
0 (0)
1 (1.2)
1 (1.2)
0 (0)
14 (16.8)
5 (6.0)
3 (3.6)
19 (22.8)
18 (21.6)
1 (1.2)
7 (8.4)
16 (19.2)
16 (19.2)
4 (4.8)
4 (4.8)
1 (1.2)
1 (1.2)
3 (3.6)
1 (1.2)
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
High Risk
7(8.4)
2(2.4)
7 (8.4)
7 (8.4)
27 (32.5)
50 (60.2)
2 (2.4)
1 (1.2)
8 (9.6)
1 (1.2)
21 (25.3)
33 (39.8)
9 (10.8)
3 (3.6)
15 (18.1)
8 (9.6)
48 (57.8)
100 (100)
>0.05
Low Risk/Negative
Total
HPV DNA Type 16 
and/or 18
1 (1.2)
16 (19.3)
17 (20.5)
< 30
> 30
Total
0 (0)
33 (39.7)
33 (39.7)
5 (6.0)
28 (33.7)
33 (39.7)
0.034
Other HPV High-
Risk Type
HPV DNA Low 
Risk/Negative
P-value*
P-value*
HSIL
LSIL
ASCH
ASCUS
Negative
Total
LBC Result
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DISCUSSION
In our study, women that performed the screening 
is between the age of 20 – 68 years old, and the 
fi rst sexual intercourse is 14 – 39 years old. Based 
on data in Indonesia, the median age of women 
that performed the sexual intercourse is 19-
21.8years old; the cigarette prevalence is 3.8%, 
hormonal contraception is  49.4%, total fertility 
birth 2.6.5
From our study, we found signifi cant differences 
in HPV DNA result among a group of age below 
30 years old and above 30 years old. The guideline 
that is used nowadays that related to the cervical 
cancer screening is included all women with the 
age of 30 and above in one category. Based on 
this research, make an important question of 
homogeneity and HPV interpretation and Pap 
test at this age. Although the proportion of 
relative abnormality in low grade and high grade 
do not change with increasing age. It showed the 
loss of conformity between HR HPV detection 
and cytology abnormality with the increasing of 
age. Decreasing of HPV prevalency between all of 
the cytology level also found with the increasing 
age in the cohort study that contributed almost 
1 million women with the age of 30 to 64 
years.2For patients below 30 years old, especially 
in adolescents and young women, screening 
adolescents leads to the unnecessary evaluation 
and potentially to the treatment of pre-invasive 
cervical lesions that have a high probability of 
regressing spontaneously.11
Several studies show that HR HPV examination 
in a low degree of the lesion in women with 
older age shows benefi cial to differentiate 
HPV infection that will grow into the precancer 
lesion. This is opposite to the study in the USA 
with RCT conclude that HR HPV screening has 
limited access to detect in low degree lesion. The 
approximate age in this study relatively young 
(27.9 years old) that makes it diffi cult to conclude 
in women above 30 years old, although from this 
study report 2x decreasing HR HPV prevalence 
in 18% of women LSIL above 30 years.2HR HPV 
type 16 and 18 need to have our attention since 
women with negative Pap and also had HPV-16 
or HPV-18, colposcopy is recommended. ASC-US 
who also had HPV-16 or HPV-18 detected had 
approximately twice the risk of CIN 3+ as women 
with ASC-US and high-risk HPV types other than 
16 or 18. Therefore, this population needs further 
colposcopy examination.
Although the presentation of HR HPV decrease 
in linear shape as related with age in the cytology 
abnormality, HPV prevalence with U shape and 
highest in the older age group. This pattern 
suggests that LR HPV dan HR HPV contributed 
to detection in patients with an older age group. 
Moreover, there is a strong relationship between 
the infection with low lever HPV and cervical 
abnormality in women with age above 45 years 
old that not seen in women with a younger age 
group. This condition is corresponding with 
observaional study before that mention the 
cervical transformation regression zone in older 
women and the high prevalence in LR HPV in 
vagina compare in cervical ephitelial.2
DNA HPV has better sensitivity. Therefore 
this could be an optional method in the HPV 
screening. A report in a cohort study with 324 
women. Sensitivity and specivicity in cervical 
cytology, colposcopy, and DNA HPV is  66.66% 
and 93.54%, 86.84% and 86.32%, and 90% and 
84.61%. With the false-negative as much as 
33.3%, 8.95%, and 10%.12 In a meta-analysis that 
compared the DNA HPV examination and cervical 
cytology with contribute 39050 participant with 
the asymptomatic clinic and 2% of pathological 
result NIS 1-2 from 11 studies, mentioned that 
the sensitivity and specifi city of DNA HPV is 94% 
and 90%, with cervical cytology 70% and 95%. 
The false-negative in DNA HPV is 1/1000 women, 
and in cytology, the cervix is  6/1000 women.13The 
epidemiology data in Indonesia, the HPV type 16 
and 18 prevalence in Indonesia is 4% in normal 
cytology and 87% in cervical cancer, and there is 
no data in HSIL and LSIL.1
The false negative in cervical cytology is 
caused by the 4 main problems, which are the 
error in the taking the sample with not taking the 
lesion part, tranfer error form the taking sample 
until the microsopic examination, error in the 
cell detection when the abnormal cell does not 
identify during the screening, the interpretation 
error when the abnormal cell detected but 
wrong interpretation. The minimal abnormal 
cell in the media could cause the false negative 
that frequently happen in the conventional Pap 
smear, with the highest error in the number of 
the abnormal cell< 30.  The availability of micro 
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biopsy or Liquid-Based Cytology (LBC)group has 
a relatively smaller false negative, which is 6% 
if compared to conventional Pap smear (14%). 
Categorized the cause od the false negative in 
the cytology interpretation into; the high density 
of the micro biopsy and hyperchromatic material 
(27.3%), discariotic cell that broken, small or 
pale (37.8%), foreign material (8.4%), low level 
of contrast (7.4%), unexplainable (5.3%).14False 
negative is more frequent to be found in tumour 
type glandular than in squamosa (52% compare 
to 16%).15
The cervical cytology and DNA HPV has better 
accuracy. In a meta-analysis of two RCTs and 
six cross-sectional studies in women with  NIS 
≥2  mention that cytology examination only 
will show sensitivity (74.3%), specifi city (95.1%) 
and false-negative(22.6%). On the other hand, 
in combination examination (cytology and DNA 
HPV) will give sensitivity (93.7%), specifi city 
(85.8%) and false negative (8.3%).16A report in the 
cross-sectional study with 615 samples showed 
that DNA HPV positive in the negative cytology 
occurred in the HPV type based on the most 
frequent: 16,18, 51, 52, 6,56, 90, 39, 66, 33, dan 
526.
This study reported routine examination in 
cervical cancer screening (cytology and DNA 
HPV) could give a different result. The HPV 
DNA test is having better sensitivity compare to 
citology. We found 32.5% of our study showed 
negative in cytology but having high-risk DNA 
result. A review reports that comparing HPV 
test and cervical smear with pooled sensitivity 
94% and 70% respectively and specifi city of 90% 
and 95% respectively.13 Other studies reported 
this discrepancy occurred among their study 
population varies around 2.2% - 6.7%.2,6,17Several 
factors including a number of subject studies, 
preparation of patients, sampling, adequacy 
in samples and pathology reading, contribute 
to our result with the previous study as our HR 
HPV (+) with Pap (-) number considered higher. 
This may increase our awareness for screening of 
precancerous lesion of the cervix.
CONCLUSION
From Pap examination, we found 32.5% negative 
cytology result with high-risk HPV DNA result. 
The highest fi ndings of HPV DNA type in our 
study was type 59 (22.8%). We found a signifi cant 
difference in HPV DNA test result among women 
above 30 years old. Co-testing of Pap and HPV 
DNA is needed, especially if HPV DNA type 16 
and 18 was found among negative Pap results.
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